Monoclonal Antibodies in Cancer Therapy: Mechanisms, Successes and Limitations

被引：46
|
作者：
Coulson, A. [1 ]
Levy, A. [1 ]
Gossell-Williams, M. [1 ]
机构：
[1] Univ W Indies, Dept Basic Med Sci, Pharmacol Sect, Kingston 7, Jamaica
来源：
WEST INDIAN MEDICAL JOURNAL | 2014年 / 63卷 / 06期
关键词：
Antigenic targets; cancer therapy; clinical benefits; monoclonal antibodies; CHRONIC LYMPHOCYTIC-LEUKEMIA; BRENTUXIMAB VEDOTIN; COLORECTAL-CANCER; LYMPHOMA; RITUXIMAB; CHEMOTHERAPY; RADIOIMMUNOTHERAPY; TRASTUZUMAB; BEVACIZUMAB; INDUCTION;
D O I：
10.7727/wimj.2013.241
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Rituximab was the first chemotherapeutic monoclonal antibody (CmAb) approved for clinical use in cancer therapeutics in 1997 and has significantly improved the clinical outcomes in non-Hodgkin's lymphoma. Since then, numerous CmAbs have been developed and approved for the treatment of various haematologic and solid human cancers. In this review, the classification, efficacy and significantly reduced toxicity of CmAbs available for use in the United States of America are presented. Finally, the limitations of CmAbs and future considerations are explored.
引用
收藏
页码：650 / 654
页数：5
相关论文
共 50 条
  • [21] The development of monoclonal antibodies for the therapy of cancer
    Farah, RA
    Clinchy, B
    Herrera, L
    Vitetta, ES
    CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION, 1998, 8 (3-4): : 321 - 356
  • [22] Monoclonal Antibodies in Oral Cancer Therapy
    Ezhilarasi, Ilamurugan
    Raj, R. R. Mahendra
    Saravanan, Thalaimalai
    Ramalingam, K. Shakila
    JOURNAL OF THE SCIENTIFIC SOCIETY, 2024, 51 (02) : 129 - 136
  • [23] Approved monoclonal antibodies for cancer therapy
    Boyiadzis, Michael
    Foon, Kenneth A.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2008, 8 (08) : 1151 - 1158
  • [24] Improving monoclonal antibodies for cancer therapy
    Robinson, MK
    Weiner, LM
    Adams, GP
    DRUG DEVELOPMENT RESEARCH, 2004, 61 (03) : 172 - 187
  • [25] Immunostimulatory monoclonal antibodies in cancer therapy
    Aranda, Fernando
    Vacchelli, Erika
    Eggermont, Alexander
    Galon, Jerome
    Fridman, Wolf Herve
    Zitvogel, Laurence
    Kroemer, Guido
    Galluzzi, Lorenzo
    ONCOIMMUNOLOGY, 2014, 3 (02):
  • [26] The promise of monoclonal antibodies for the therapy of cancer
    Gutheil, J
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2001, 38 (01) : 1 - 2
  • [27] Novel targets and monoclonal antibodies for cancer therapy
    Grandi, Alberto
    Parri, Matteo
    Campagnoli, Susanna
    Nogarotto, Renzo
    De Camilli, Elisa
    Naldi, Ilaria
    Cinti, Caterina
    Sarmientos, Paolo
    Grandi, Guido
    Terracciano, Luigi
    Viale, Giuseppe
    Pileri, Piero
    Grifantini, Renata Maria
    CANCER RESEARCH, 2013, 73 (08)
  • [28] CHALLENGES TO THE THERAPY OF CANCER WITH MONOCLONAL-ANTIBODIES
    GOLDENBERG, DM
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1991, 83 (02) : 78 - 79
  • [29] Monoclonal antibodies for targeted therapy in colorectal cancer
    Banerjee, Sreeparna
    Flores-Rozas, Hernan
    CANCER BIOLOGY & THERAPY, 2010, 9 (08) : 563 - 571
  • [30] Trial watch Monoclonal antibodies in cancer therapy
    Vacchelli, Erika
    Eggermont, Alexander
    Galon, Jerome
    Sautes-Fridman, Catherine
    Zitvogel, Laurence
    Kroemer, Guido
    Galluzzi, Lorenzo
    ONCOIMMUNOLOGY, 2013, 2 (01):
12345